The database
Compounds
149 compounds and 7 stacks, grouped by what people use them for. Every page cites its sources.
- Stacks7
- Fat loss37
- Muscle & growth hormone20
- Tendon & gut repair12
- Skin & hair23
- Mind & sleep18
- Brain & nerves9
- Hormones & libido16
- Longevity21
- Immune12
- Bioregulators19
Stacks 7
- Mind & sleepChecked Oct 4Flow StateThe focus-and-sleep stack for when Adderall isn't an option. Trials of the three together: zero.Evidence · No dataGray market
- Muscle & growth hormoneChecked Oct 4GH StackCJC-1295 + ipamorelin, the classic gray-market GH pair. Trials of the pair itself: zero.Evidence · No dataGray market
- Skin & hairChecked Oct 4GLOW StackWolverine plus a copper peptide, sold for skin, scars and hair. Human trials of the three together: zero.Evidence · No dataGray market
- Tendon & gut repairChecked Oct 4KLOW StackGLOW with an anti-inflammatory peptide added, run as one 80 mg vial. Human trials of the four together: zero.Evidence · No dataGray market
- LongevityChecked Oct 4Mito StackSold as software, hardware and fuel for tired mitochondria. Trials of the three together: zero.Evidence · No dataGray market
- Muscle & growth hormoneChecked Oct 4Tesa/IpaTesamorelin + ipamorelin, sold as a one-vial GH blend. Trials of the pair itself: zero.Evidence · No dataGray market
- Tendon & gut repairChecked Oct 5Wolverine StackThe most-run recovery stack: BPC-157 plus TB-500. Human trials of the pair: zero, after about 15 years.Evidence · Animal onlyGray market
Fat loss 37
- Fat lossChecked Oct 5LiraglutideThe daily shot before Ozempic, approved for teenagers from 12. Its main trial: 8% weight loss at 56 weeks.Evidence · Approved drugFDA approved
- Fat lossChecked Oct 4OrforglipronFoundayo: a daily weight-loss pill with no fasting rules. Phase 3: 11.2% weight loss at 72 weeks.Evidence · Approved drugFDA approved
- Fat lossChecked Oct 5SemaglutideThe weekly shot the FDA approved as Ozempic and Wegovy. Weight loss in its main trial: 14.9%, on average.Evidence · Approved drugFDA approved
- Fat lossChecked Oct 4SetmelanotideFor rare genetic obesity, not everyday weight loss. Phase 3: 8 of 10 patients lost at least 10% in a year.Evidence · Approved drugFDA approved
- Muscle & growth hormoneChecked Oct 4TesamorelinApproved for HIV-related belly fat; clinics use it off-label. Its 412-patient trial cut belly fat 15–18%.Evidence · Approved drugFDA approved
- Fat lossChecked Oct 5TirzepatideZepbound: the weekly shot that beat semaglutide head-to-head. Main trial: 20.9% weight loss at 72 weeks.Evidence · Approved drugFDA approved
- Fat lossChecked Oct 4AmycretinNovo's next weight-loss shot and pill, trials only. Every published result: Novo-funded trials, 759 people.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4AOD-9604Sold as growth hormone's fat-burning fragment. Its biggest trial, 502 people over 24 weeks, missed its goal.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5BimagrumabPitched as fat loss that keeps muscle. Alone, it took off less weight than semaglutide in a 507-adult trial.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5CagrilintideThe other half of Novo's CagriSema combo. Alone it's gray-market; paired, 20.4% weight loss at 68 weeks.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5CagriSemaNovo's two-drug shot built to beat Zepbound. 20.4% weight loss in Phase 3; the FDA hasn't ruled yet.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5DulaglutideTrulicity: a weekly diabetes shot, not a weight-loss drug. The AWARD trials: 2–5 kg lost.Evidence · Controlled trialsFDA approved
- Fat lossChecked Oct 4EcnoglutideChina's weekly weight-loss shot, billed as beating semaglutide. The proof: a conference poster at week 20.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4EloralintideLilly's next weight-loss shot, in trials only. Phase 2: 20% weight loss at 48 weeks in 263 adults.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5ExenatideByetta, the diabetes shot copied from Gila monster venom. Obese, no diabetes: 3.3% of weight beyond placebo.Evidence · Controlled trialsFDA approved
- Fat lossChecked Oct 4MariTideAmgen's bid for a once-a-month obesity shot. In print so far: one efficacy trial, 592 people, Amgen-funded.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4MazdutidePrescribed in China since 2025; not approved in the US. Main trial: 12.6% weight loss at 32 weeks.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4PemvidutideAltimmune's two-in-one weight-loss shot, in trials only. Phase 2: 15.6% loss at 48 weeks in 391 adults.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5PetrelintidePitched as the weight-loss shot you can stay on. Phase 2: 9.8% at 28 weeks against 1.7% on placebo.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4PramlintideApproved in 2005 for diabetics on insulin: three shots a day, boxed warning. Not a weight-loss drug.Evidence · Controlled trialsFDA approved
- Fat lossChecked Oct 5RetatrutideLilly's triple-hormone shot, unapproved; gray-market copies sell anyway. Phase 3: 25.0% loss at 80 weeks.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4SurvodutideBoehringer's two-in-one weight-loss shot, in Phase 3. Phase 2 beat placebo by up to 12 points of body weight.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4TesofensineBack on the gray market since the weight-loss-shot shortages. Phase 2: 9.2% loss in 24 weeks; no Phase 3.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 5VK2735Viking's rival to Mounjaro, in trials only. Phase 2: 14.7% weight loss in 13 weeks at the top dose.Evidence · Controlled trialsGray market
- Fat lossChecked Oct 4CardarineTaken as an exercise pill for fat loss. Its maker quit after 2-year rodent tests found tumors at every dose.Tumors in rats and mice at every doseEvidence · Human pilotsGray market
- Fat lossChecked Oct 5CT-388Roche's weekly weight-loss shot, still in trials. Phase 2 poster, top dose: 18.3% beyond placebo at 48 weeks.Evidence · Human pilotsGray market
- Fat lossChecked Oct 4GlumitideLilly's trial-only shot, built from one half of Zepbound. Data: two Phase 1 studies, four weeks of dosing.Evidence · Human pilotsGray market
- Fat lossChecked Oct 55-Amino-1MQSold as a fat-loss pill for a stubborn metabolism. Every fat-loss result so far: obese mice, from one lab.Evidence · Animal onlyGray market
- Fat lossChecked Oct 4AdipotidePitched as a way to starve fat cells of blood. Obese monkeys lost 11% of their fat; their kidneys objected.Kidney damage in primate trialsEvidence · Animal onlyGray market
- Fat lossChecked Oct 5AICARSold as exercise in a pill. The 2008 mice ran 44% farther; no human trial has matched it.Evidence · Animal onlyGray market
- Fat lossChecked Oct 5BAM15A research chemical that makes mitochondria waste fuel. In mice it stopped fat gain; human trials: zero.Evidence · Animal onlyGray market
- Fat lossChecked Oct 4GW-0742A PPAR-delta agonist pitched as exercise in a pill. The evidence: mouse muscle papers; human trials: zero.Evidence · Animal onlyGray market
- Fat lossChecked Oct 4HGH Fragment 176-191Sold as 'HGH frag' for fat loss. Human trials of this exact fragment: zero; its cousin AOD-9604 failed.Evidence · Animal onlyGray market
- LongevityChecked Oct 5MOTS-cA peptide from mitochondrial DNA, pitched as exercise in a bottle. Human trials of it injected: zero.Evidence · Animal onlyGray market
- Fat lossChecked Oct 4Nesfatin-1Studied since 2006 as an appetite brake. It has never been given to a person in a trial.Evidence · Animal onlyGray market
- Fat lossChecked Oct 5SLU-PP-332A pill pitched as a workout substitute. The evidence: one 2023 mouse paper where mice ran 70% farther.Evidence · Animal onlyGray market
- Fat lossChecked Oct 4SR9009Sold online as exercise in a pill. The fat loss came from mice injected for 30 days; no human trial.Case report: liver failure, transplantEvidence · Animal onlyGray market
Muscle & growth hormone 20
- Muscle & growth hormoneChecked Oct 5HGHAnti-aging clinics sell it for body composition. That story began with 12 men in a 1990 study.Evidence · Approved drugFDA approved
- Muscle & growth hormoneChecked Oct 4TesamorelinApproved for HIV-related belly fat; clinics use it off-label. Its 412-patient trial cut belly fat 15–18%.Evidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 5TestosteronePrescribed for low testosterone; also the original anabolic steroid. Normal is 300–1,000 ng/dL.Evidence · Approved drugFDA approved
- Muscle & growth hormoneChecked Oct 5ACE-031Sold to lifters as a muscle-brake blocker. Top dose: lean mass +3.3% in women 45–75; a boys’ trial stopped.Trial halted over bleeding eventsEvidence · Controlled trialsGray market
- Muscle & growth hormoneChecked Oct 5AnamorelinJapan’s Adlumiz, a pill for cancer wasting. In 979 lung-cancer patients, lean mass rose; grip strength didn’t.Heart-rhythm emergencies in case reportsEvidence · Controlled trialsGray market
- Fat lossChecked Oct 5BimagrumabPitched as fat loss that keeps muscle. Alone, it took off less weight than semaglutide in a 507-adult trial.Evidence · Controlled trialsGray market
- Muscle & growth hormoneChecked Oct 5GHRP-2Clinic users inject it 2–3 times a day. Its only approval: a one-shot growth-hormone test in Japan, 2004.Evidence · Controlled trialsGray market
- Muscle & growth hormoneChecked Oct 5MK-677Taken nightly for growth hormone and sleep. A year-long trial: +1.1 kg lean mass, no strength gain.Trial halted over heart failureEvidence · Controlled trialsGray market
- Muscle & growth hormoneChecked Oct 5SermorelinThe first FDA-approved growth-hormone releaser, now compounded for adults. The approval was for kids, 1997.Evidence · Controlled trialsCompounding pharmacy
- Muscle & growth hormoneChecked Oct 4CJC-1295Anti-aging clinics pair it with ipamorelin for growth hormone. Human data: 78 people in three Phase 1 trials.Evidence · Human pilotsGray market
- Muscle & growth hormoneChecked Oct 5GHRP-6The 1984 original, now taken mostly for its hunger kick. Its human data: single-dose growth-hormone tests.Evidence · Human pilotsGray market
- Muscle & growth hormoneChecked Oct 4HexarelinKnown for the biggest growth-hormone pulse of its family. The catch: it fades within 2–4 weeks of daily use.Evidence · Human pilotsGray market
- Muscle & growth hormoneChecked Oct 5IpamorelinSold as the polite growth-hormone releaser that spares cortisol. That claim traces to a 1998 study in pigs.Evidence · Human pilotsGray market
- Muscle & growth hormoneChecked Oct 5MacimorelinMacrilen: a drink that tests adults for low growth hormone. It missed 19 of 74 the insulin test flagged.Evidence · Human pilotsFDA approved
- Muscle & growth hormoneChecked Oct 5Follistatin-344Bodybuilders buy vials to lift the body's muscle brake. Controlled human trials of vial follistatin: zero.Evidence · Animal onlyGray market
- Muscle & growth hormoneChecked Oct 5IGF-1 DESBodybuilders inject it into a muscle for 'spot growth'. Human studies of it: zero; it lasts 20–30 minutes.Evidence · Animal onlyGray market
- Muscle & growth hormoneChecked Oct 5IGF-1 LR3Taken by advanced lifters for muscle growth. Randomized human trials of this version: zero.Evidence · Animal onlyGray market
- Muscle & growth hormoneChecked Oct 4MGFLifters inject it into a muscle right after training. Human trials: zero; it lasts 5–7 minutes.Evidence · Animal onlyGray market
- Muscle & growth hormoneChecked Oct 4PEG-MGFLonger-lasting MGF, taken with BPC-157 or TB-500 by strength crowds. Human trials: zero.Evidence · Animal onlyGray market
- Muscle & growth hormoneChecked Oct 5FLGR-242A codenamed follistatin, sold by the company its promoter co-founded. Published studies of it: zero.Evidence · No dataGray market
Tendon & gut repair 12
- Tendon & gut repairChecked Oct 5TeduglutideGattex, prescribed for short bowel syndrome. Main trial: 63% cut IV support by at least a fifth; placebo, 30%.Evidence · Approved drugFDA approved
- Tendon & gut repairChecked Oct 5AbaloparatideTymlos, for fragile bones, was tested on broken ones. 48 pelvic-fracture patients: no better than placebo.Evidence · Controlled trialsFDA approved
- Tendon & gut repairChecked Oct 5LarazotidePromoted online for IBD and celiac. In its largest trial 1 of 3 doses beat placebo; Phase 3 stopped in 2022.Evidence · Controlled trialsGray market
- Tendon & gut repairChecked Oct 5TeriparatideForteo, Lilly's osteoporosis shot, tried on fractures. In 159 hip-fracture patients, healing matched placebo.Evidence · Controlled trialsFDA approved
- Tendon & gut repairChecked Oct 5BPC-157Every stubborn-injury guy keeps one in the fridge. 393 papers so far, almost all of them in rats.Evidence · Human pilotsGray market
- Tendon & gut repairChecked Oct 5B7-33A cut-down piece of the human hormone relaxin, built to cut scarring. Human trials: zero; mice and rats.Evidence · Animal onlyGray market
- Tendon & gut repairChecked Oct 4CartalaxTaken in Khavinson cycles for the joints. The evidence: rat cartilage cells in a dish, zero human trials.Evidence · Animal onlyGray market
- ImmuneChecked Oct 5KPVTaken for gut and skin flares. Its best evidence: two 2008 mouse-colitis papers; human trials: zero.Evidence · Animal onlyGray market
- Tendon & gut repairChecked Oct 5TB-500Injected for tendons alongside BPC-157. What's sold is a 7-amino-acid fragment with zero human studies.Evidence · Animal onlyGray market
- Tendon & gut repairChecked Oct 5Thymosin Beta-4TB-500’s parent protein, sold for injury repair. In 700 dry-eye patients its eye drops missed both main goals.Evidence · Animal onlyGray market
- Tendon & gut repairChecked Oct 5BPC-157 FragmentSold as a cheaper cut of BPC-157. Peer-reviewed studies of the fragment itself: zero.Evidence · No dataGray market
- Tendon & gut repairChecked Oct 4Pentadeca ArginateClinics sell it as the new BPC for injuries. Peer-reviewed studies of it: 0.Evidence · No dataGray market
Skin & hair 23
- Skin & hairChecked Oct 4Melanotan ITanners inject the gray-market version. The approved one is a 16 mg implant for a rare sun allergy.Evidence · Approved drugFDA approved
- Skin & hairChecked Oct 5EGFGrowth factor in face serums and Cuba’s ulcer drug Heberprot-P. Its double-blind acne trial: 20 people.Evidence · Controlled trialsGray market
- Skin & hairChecked Oct 5MatrixylA wrinkle peptide in 239 US cosmetics (2023). Its largest trial on its own, run by Procter & Gamble: 93 women.Evidence · Controlled trialsGray market
- Skin & hairChecked Oct 5ArgirelineSold as Botox in a jar. FDA researchers found about 0.22% of it reaches living skin.Evidence · Human pilotsGray market
- Skin & hairChecked Oct 4Decapeptide-12Sold in creams for melasma and dark spots. Its best trial: five women, one split-face study.Evidence · Human pilotsGray market
- Skin & hairChecked Oct 5GHK-CuSold in serums and injected off-label for hair. Its human trials: 12-week face creams, not injections.Evidence · Human pilotsGray market
- LongevityChecked Oct 4GlutathioneSold as an IV drip at wellness clinics. Its best trial: 54 adults, oral doses, body stores up over 6 months.Evidence · Human pilotsCompounding pharmacy
- Hormones & libidoChecked Oct 4Melanotan IIInjected for a sunless tan and a libido kick. The tanning trial behind it had 3 people, in 1996.Mole changes in case reportsEvidence · Human pilotsGray market
- Skin & hairChecked Oct 4Pentapeptide-18Sold in wrinkle serums with Argireline. Its maker's 28-day test: 11.64% shallower wrinkles in 14 volunteers.Evidence · Human pilotsGray market
- Skin & hairChecked Oct 4AHK-CuSold in hair-growth serums as GHK-Cu's scalp cousin. The whole case rests on one 2007 lab paper.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4GHK BasicGHK-Cu without the copper, for creams that also carry vitamin C. Randomized human trials of it: zero.Evidence · Animal onlyGray market
- ImmuneChecked Oct 5KPVTaken for gut and skin flares. Its best evidence: two 2008 mouse-colitis papers; human trials: zero.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4Nonapeptide-1Sold in brightening creams at 1–2%. Independent human trials: zero; the data are the maker's.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4Pal-GHKHalf of the Matrixyl 3000 combo. Its best evidence is a 93-woman trial of a different peptide.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4RiginHalf of Matrixyl 3000, sold as anti-inflammaging. Trials of Rigin alone: zero; the data are the supplier's.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4SNAP-8A longer Argireline analog, sold in wrinkle creams. Peer-reviewed human trials: zero.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4Syn-AkeA snake-venom mimic in wrinkle creams. Its evidence: the maker's own 28-day panels.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4Syn-CollUsed at 2–4% in serums to push collagen. The claims come from supplier studies; independent trials: zero.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4Tripeptide-29A collagen fragment in creams, at 1–5%. Trials of creams with it as the active: zero.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4VialoxSold as a Botox alternative. Its '49% wrinkle reduction' is a supplier figure; peer-reviewed trials: zero.Evidence · Animal onlyGray market
- Skin & hairChecked Oct 4Waglerin-1A lethal pit-viper neurotoxin, studied in labs. Wrinkle creams use a small mimic; human trials: zero.Lethal snake-venom neurotoxinEvidence · Animal onlyGray market
- Skin & hairChecked Oct 4Pal-AHKUsed in hair serums, copper-free. Peer-reviewed trials of this version: zero.Evidence · No dataGray market
- Skin & hairChecked Oct 4Palmitoyl Dipeptide-6Sold in firming serums at 1–4%. Peer-reviewed trials: zero; the claims come from supplier dossiers.Evidence · No dataGray market
Mind & sleep 18
- Mind & sleepChecked Oct 4BromantaneRussian doctors prescribe it for burnout and fatigue. Every trial so far is Russian; WADA banned it in 1997.Evidence · Controlled trialsGray market
- Mind & sleepChecked Oct 4DSIPInjected before bed for deeper sleep. A 1992 double-blind insomnia trial called it 'not likely' to help.Evidence · Controlled trialsGray market
- Mind & sleepChecked Oct 5OxytocinA nose spray pitched for mood and bonding. Approved in 1962 for labor; the nasal-spray trials are split.Evidence · Controlled trialsFDA approved
- Mind & sleepChecked Oct 5SelankRussian nasal drops for anxiety, approved there in 2009. Every trial so far is Russian.Evidence · Controlled trialsGray market
- Muscle & growth hormoneChecked Oct 5IpamorelinSold as the polite growth-hormone releaser that spares cortisol. That claim traces to a 1998 study in pigs.Evidence · Human pilotsGray market
- Mind & sleepChecked Oct 4Methylene BlueBiohackers take drops for brain energy. Its one brain study: a single 280 mg dose, 26 people, in 2016.Evidence · Human pilotsFDA approved
- Mind & sleepChecked Oct 5NoopeptSold in US supplements as a memory booster. 20 years on the Russian market; no placebo trial published.Evidence · Human pilotsGray market
- Mind & sleepChecked Oct 5PinealonUsed in Russia after brain injury. Its best study: a 72-patient Russian report in the developers' patent.Evidence · Human pilotsGray market
- Mind & sleepChecked Oct 5SemaxA Russian stroke drug that biohackers spray for focus. Its key stroke trial had 30 patients, in 1997.Evidence · Human pilotsGray market
- Brain & nervesChecked Oct 5CortagenA synthetic Cortexin, Russia's brain drug. Its best result: rat nerves regrew 27% faster, in one lab.Evidence · Animal onlyGray market
- Brain & nervesChecked Oct 5Cyclic Glycine-ProlineA two-amino-acid ring sold in blackcurrant capsules for the brain. Its 126-person trial posted no results.Evidence · Animal onlyGray market
- Mind & sleepChecked Oct 5DihexaA lab molecule pitched as a memory drug. Human trials: zero.Evidence · Animal onlyGray market
- Mind & sleepChecked Oct 4FGLSold to nootropic buyers as a memory peptide. Its only published human study: a safety test in 24 men.Neuron loss in healthy young ratsEvidence · Animal onlyGray market
- Mind & sleepChecked Oct 4N-Acetyl SelankA capped Selank, sold for anxiety. Studies of the capped version: zero.Evidence · Animal onlyGray market
- Mind & sleepChecked Oct 4N-Acetyl SemaxSold as a longer-lasting Semax. Trials of the capped version: zero; the parent has two Russian stroke trials.Evidence · Animal onlyGray market
- Mind & sleepChecked Oct 4P21Nootropic buyers order it for new brain cells. Fifteen papers, one lab, mice only; human trials: zero.Evidence · Animal onlyGray market
- Mind & sleepChecked Oct 5PE-22-28Pitched as a fast antidepressant, sold as a nasal spray. Human trials: zero; its mood data are one lab’s mice.Evidence · Animal onlyGray market
- Mind & sleepChecked Oct 4DS5A vendor-made nasal spray of Dihexa and Semax. Trials of the blend: zero, and the ratios vary by vendor.Evidence · No dataGray market
Brain & nerves 9
- Brain & nervesChecked Oct 5ARA-290Chased by people with small-fiber nerve pain. Two Phase 2 trials, 28 days each; no Phase 3 yet.Evidence · Controlled trialsGray market
- Brain & nervesChecked Oct 5CerebrolysinPig-brain extract given for stroke recovery abroad. 90 trials in PubMed; Cochrane found no effect on deaths.Evidence · Controlled trialsGray market
- Brain & nervesChecked Oct 5CortexinCattle-brain peptides prescribed in Russia for stroke. Trial deaths: 7 of 208 on it, none of 64 on placebo.Evidence · Controlled trialsGray market
- Mind & sleepChecked Oct 5NoopeptSold in US supplements as a memory booster. 20 years on the Russian market; no placebo trial published.Evidence · Human pilotsGray market
- Mind & sleepChecked Oct 5PinealonUsed in Russia after brain injury. Its best study: a 72-patient Russian report in the developers' patent.Evidence · Human pilotsGray market
- Mind & sleepChecked Oct 5SemaxA Russian stroke drug that biohackers spray for focus. Its key stroke trial had 30 patients, in 1997.Evidence · Human pilotsGray market
- Brain & nervesChecked Oct 5CortagenA synthetic Cortexin, Russia's brain drug. Its best result: rat nerves regrew 27% faster, in one lab.Evidence · Animal onlyGray market
- Brain & nervesChecked Oct 5Cyclic Glycine-ProlineA two-amino-acid ring sold in blackcurrant capsules for the brain. Its 126-person trial posted no results.Evidence · Animal onlyGray market
- Brain & nervesChecked Oct 5DNSP-11Eleven amino acids copied from a brain growth protein, for Parkinson's. Human trials: zero; monkeys: three.Evidence · Animal onlyGray market
Hormones & libido 16
- Hormones & libidoChecked Oct 4ClomipheneMen take a women's fertility pill off-label to raise testosterone. Approved since 1967, for women only.Vision changes may be irreversibleEvidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 5DesmopressinDDAVP: prescribed for a missing water hormone. Of 215 clinic patients, 30.7% had low sodium over 12 months.Low blood sodium can be fatalEvidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 5EPOSold as Epogen for anemia; athletes dope with EPO. In 48 trained cyclists, EPO didn't beat placebo in a race.Boxed warning: death, stroke, clotsEvidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 4HCGMen on testosterone use it to stay fertile. The standard 500 IU every-other-day dose comes from a 2005 study.Evidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 4HMGUrine-derived hormones men add to hCG to make sperm. FDA-approved only for women's IVF, 20 days max.Evidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 4Insulin8 million Americans need it for diabetes; some bodybuilders inject it for size. Misuse can kill.Hypoglycemia can be fatalEvidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 4PT-141Approved for women's low desire, used mostly off-label by men. The approval trials: 1,247 women, zero men.Evidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 5TestosteronePrescribed for low testosterone; also the original anabolic steroid. Normal is 300–1,000 ng/dL.Evidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 4TriptorelinBodybuilders use one shot to 'restart' testosterone. It's approved to shut testosterone off, within 3–4 weeks.Evidence · Approved drugFDA approved
- Hormones & libidoChecked Oct 4Enclomiphene CitrateMen's clinics prescribe it to raise testosterone and keep fertility. The FDA turned it down in 2015.Evidence · Controlled trialsCompounding pharmacy
- Hormones & libidoChecked Oct 4GonadorelinClinics swap it in for hCG on TRT. It lasts 2–10 minutes in the blood, and studies of that use are thin.Evidence · Controlled trialsCompounding pharmacy
- Hormones & libidoChecked Oct 4KisspeptinClinics sell it as a TRT add-on. Its Phase 2 trials, from two hospital groups, never tested that.Evidence · Controlled trialsGray market
- Hormones & libidoChecked Oct 4Melanotan IIInjected for a sunless tan and a libido kick. The tanning trial behind it had 3 people, in 1996.Mole changes in case reportsEvidence · Human pilotsGray market
- Hormones & libidoChecked Oct 5ProstamaxSold online for prostate trouble. Peer-reviewed human studies: zero; two patents, rat tissue, cells in a dish.Evidence · Animal onlyGray market
- Hormones & libidoChecked Oct 5TestagenTaken in Russia for falling testosterone. The evidence: chickens from one lab, plus one 36-man Russian report.Evidence · Animal onlyGray market
- Hormones & libidoChecked Oct 4ZuclomipheneClomiphene's other half, tested for hot flashes. Its only Phase 2 result is an unpublished interim readout.Evidence · Animal onlyGray market
Longevity 21
- Muscle & growth hormoneChecked Oct 5HGHAnti-aging clinics sell it for body composition. That story began with 12 men in a 1990 study.Evidence · Approved drugFDA approved
- LongevityChecked Oct 4EpithalonRussia's longevity peptide, taken in 10-day courses. Its famous 266-person study tested the pineal extract.Evidence · Human pilotsGray market
- LongevityChecked Oct 4GlutathioneSold as an IV drip at wellness clinics. Its best trial: 54 adults, oral doses, body stores up over 6 months.Evidence · Human pilotsCompounding pharmacy
- LongevityChecked Oct 4NAD+Clinics sell it by IV because levels halve between 20 and 60. The trials mostly tested pills, not drips.Evidence · Human pilotsCompounding pharmacy
- Mind & sleepChecked Oct 5PinealonUsed in Russia after brain injury. Its best study: a 72-patient Russian report in the developers' patent.Evidence · Human pilotsGray market
- LongevityChecked Oct 4SS-31Approved in 2025 for a rare mitochondrial disease. Off-label longevity use rests on Phase 2 data.Evidence · Human pilotsFDA approved
- ImmuneChecked Oct 4ThymalinA calf-thymus extract used in Russia since 1982. Its famous 266-person aging study came from its developers.Evidence · Human pilotsGray market
- LongevityChecked Oct 4BronchogenLongevity fans take it in capsule cycles for the lungs. Randomized human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 4CardiogenLongevity fans run 10–20 day capsule cycles for the heart. Randomized human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 4ChonlutenTaken with Bronchogen in Khavinson cycles for the airways. Randomized human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 5FOXO4-DRISold to longevity buyers as a zombie-cell killer. Human data: none; one 2017 mouse paper started it.Evidence · Animal onlyGray market
- LongevityChecked Oct 4HumaninA mitochondrial peptide sold for longevity. Twenty years of cell and rodent work; human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 4KlothoSold as the protein that made mice live longer. Tested on 18 old monkeys' memory; no published human study.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4LivagenPitched for liver and immune support in Khavinson cycles. Good randomized human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 5MOTS-cA peptide from mitochondrial DNA, pitched as exercise in a bottle. Human trials of it injected: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 4N-Acetyl-EpithalonEpithalon with chemical caps, sold as longer-lasting. Human studies of the capped version: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 5OvagenTaken for liver and gut support. One lab's research, zero human trials; nothing to do with ovaries.Evidence · Animal onlyGray market
- LongevityChecked Oct 4PancragenUsed in Russian clinics alongside diabetes care. The evidence: 20 years of Russian case series.Evidence · Animal onlyGray market
- LongevityChecked Oct 4VesugenUsed in Khavinson cycles for blood vessels. The evidence: cell studies and three small Russian reports.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4VilonA Khavinson dipeptide taken in cycles for immunity. Randomized human trials of it alone: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 5VesiluteA two-amino-acid peptide sold in Russia for the bladder. Peer-reviewed studies in animals or people: zero.Evidence · No dataGray market
Immune 12
- ImmuneChecked Oct 4Thymosin Alpha-1Approved abroad for hepatitis B and as an immune enhancer. Its 1,106-patient sepsis trial: no fewer deaths.Evidence · Controlled trialsGray market
- ImmuneChecked Oct 4ThymagenTwo amino acids, sold in Moscow pharmacies as Thymogen for immunity. Western randomized trials: zero.Evidence · Human pilotsGray market
- ImmuneChecked Oct 4ThymalinA calf-thymus extract used in Russia since 1982. Its famous 266-person aging study came from its developers.Evidence · Human pilotsGray market
- ImmuneChecked Oct 5ThymulinA zinc-charged thymus hormone, often confused with Thymalin. 50 years of research, mostly in rodents.Evidence · Human pilotsGray market
- ImmuneChecked Oct 5CrystagenSold in Russia as an immune-support supplement capsule. Placebo-controlled human trials: zero.Evidence · Animal onlyGray market
- ImmuneChecked Oct 5KPVTaken for gut and skin flares. Its best evidence: two 2008 mouse-colitis papers; human trials: zero.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4LivagenPitched for liver and immune support in Khavinson cycles. Good randomized human trials: zero.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4LL-37Injected for immune support. Its roughly 10 small human trials tested it on leg ulcers, not in shots.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4Neurokinin AInhaled in labs to tighten airways and test asthma drugs. Not a therapy: the 3 drugs in its family block it.Evidence · Animal onlyGray market
- ImmuneChecked Oct 5PNC-27Sold online as a cancer cure. Human trials: zero; FDA found bacteria in a sample it tested.FDA warned patients against itEvidence · Animal onlyGray market
- ImmuneChecked Oct 4VilonA Khavinson dipeptide taken in cycles for immunity. Randomized human trials of it alone: zero.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4VIPSprayed up the nose for mold illness (CIRS). Two large Phase 3 trials for other uses failed.Evidence · Animal onlyCompounding pharmacy
Bioregulators 19
- Brain & nervesChecked Oct 5CortexinCattle-brain peptides prescribed in Russia for stroke. Trial deaths: 7 of 208 on it, none of 64 on placebo.Evidence · Controlled trialsGray market
- LongevityChecked Oct 4EpithalonRussia's longevity peptide, taken in 10-day courses. Its famous 266-person study tested the pineal extract.Evidence · Human pilotsGray market
- Mind & sleepChecked Oct 5PinealonUsed in Russia after brain injury. Its best study: a 72-patient Russian report in the developers' patent.Evidence · Human pilotsGray market
- ImmuneChecked Oct 4ThymagenTwo amino acids, sold in Moscow pharmacies as Thymogen for immunity. Western randomized trials: zero.Evidence · Human pilotsGray market
- ImmuneChecked Oct 4ThymalinA calf-thymus extract used in Russia since 1982. Its famous 266-person aging study came from its developers.Evidence · Human pilotsGray market
- LongevityChecked Oct 4BronchogenLongevity fans take it in capsule cycles for the lungs. Randomized human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 4CardiogenLongevity fans run 10–20 day capsule cycles for the heart. Randomized human trials: zero.Evidence · Animal onlyGray market
- Tendon & gut repairChecked Oct 4CartalaxTaken in Khavinson cycles for the joints. The evidence: rat cartilage cells in a dish, zero human trials.Evidence · Animal onlyGray market
- LongevityChecked Oct 4ChonlutenTaken with Bronchogen in Khavinson cycles for the airways. Randomized human trials: zero.Evidence · Animal onlyGray market
- Brain & nervesChecked Oct 5CortagenA synthetic Cortexin, Russia's brain drug. Its best result: rat nerves regrew 27% faster, in one lab.Evidence · Animal onlyGray market
- ImmuneChecked Oct 5CrystagenSold in Russia as an immune-support supplement capsule. Placebo-controlled human trials: zero.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4LivagenPitched for liver and immune support in Khavinson cycles. Good randomized human trials: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 5OvagenTaken for liver and gut support. One lab's research, zero human trials; nothing to do with ovaries.Evidence · Animal onlyGray market
- LongevityChecked Oct 4PancragenUsed in Russian clinics alongside diabetes care. The evidence: 20 years of Russian case series.Evidence · Animal onlyGray market
- Hormones & libidoChecked Oct 5ProstamaxSold online for prostate trouble. Peer-reviewed human studies: zero; two patents, rat tissue, cells in a dish.Evidence · Animal onlyGray market
- Hormones & libidoChecked Oct 5TestagenTaken in Russia for falling testosterone. The evidence: chickens from one lab, plus one 36-man Russian report.Evidence · Animal onlyGray market
- LongevityChecked Oct 4VesugenUsed in Khavinson cycles for blood vessels. The evidence: cell studies and three small Russian reports.Evidence · Animal onlyGray market
- ImmuneChecked Oct 4VilonA Khavinson dipeptide taken in cycles for immunity. Randomized human trials of it alone: zero.Evidence · Animal onlyGray market
- LongevityChecked Oct 5VesiluteA two-amino-acid peptide sold in Russia for the bladder. Peer-reviewed studies in animals or people: zero.Evidence · No dataGray market
Nothing here matches “”. Try the name printed on the vial, a trade name, or a shorter part of it.